Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052089 | 0.82 | PTGS2 (0.48) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL4666990 | 0.72 | KMT2A (0.52) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL822762 | 0.71 | SMN1; SMN2 (0.55) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL5673134 | 0.70 | MGLL (0.52) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL9568787 | 0.69 | HSD11B1 (0.46) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL12781922 | 0.69 | MGLL (0.51) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL27701526 | 0.68 | SLC9A1 (0.51) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL23113874 | 0.67 | ALDH1A1 (0.50) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL5698916 | 0.67 | ALDH1A1 (0.50) | PTGS2ALDH1A1TSHRPOLBHTT | |
| SCHEMBL4407324 | 0.67 | ALDH1A1 (0.50) | PTGS2ALDH1A1TSHRPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108778341-B | Amanita conjugates | 海德堡医药研究有限责任公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3423104-B1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RES GMBH (DE) | 2022-05-18 | — | — | EP | claimed |
| EP-4611897-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | Heidelberg Pharma Research GmbH (DE) | 2025-09-10 | — | — | EP | disclosed |
| EP-3665173-B1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RES GMBH (DE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4504270-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX OF AMATOXIN-ANTIBODY CONJUGATES | Heidelberg Pharma Research GmbH (DE) | 2025-02-12 | — | — | EP | disclosed |
| US-12201693-B2 | Amanitin conjugates | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-01-21 | — | — | US | disclosed |
| EP-3661938-B1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RES GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| US-11926631-B2 | Method of treating cancer using amanitin derivatives | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-03-12 | — | — | US | disclosed |
| EP-3268047-B9 | AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA RES GMBH (DE) | 2024-01-10 | — | — | EP | disclosed |
| CN-117241832-A | B lymphocyte-specific amatoxin antibody conjugates | 海德堡医药研究有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2019030173-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA GMBH (DE) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019030171-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA GMBH (DE) | 2019-02-14 | — | — | WO | disclosed |
| EP-3423104-A1 | AMANITIN CONJUGATES | Heidelberg Pharma Research GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180346519-A1 | Derivatives of Gamma-Amanitin | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| EP-3380451-A1 | DERIVATIVES OF GAMMA-AMANITIN | Heidelberg Pharma Research GmbH (DE) | 2018-10-03 | — | — | EP | disclosed |
| US-20180043033-A1 | AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| EP-3268047-A1 | AMATOXIN-ANTIBODY CONJUGATES | Heidelberg Pharma GmbH (DE) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017089607-A1 | DERIVATIVES OF GAMMA-AMANITIN | HEIDELBERG PHARMA GMBH (DE) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016142049-A1 | AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA GMBH (DE) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180043033-A1 | AMATOXIN-ANTIBODY CONJUGATES | C3AR1, ANTXR2, MTX2 | PTGS2 4624/4885ALDH1A1 2955/4885TSHR 956/4885 |
| US-12201693-B2 | Amanitin conjugates | CD47, MTX1, SIGLEC7 | PTGS2 4800/4885ALDH1A1 3297/4885TSHR 1569/4885 |
| US-20180346519-A1 | Derivatives of Gamma-Amanitin | MGAT2, MGAT3, MGAT1 | PTGS2 3757/4885ALDH1A1 2929/4885TSHR 1422/4885 |
| US-11926631-B2 | Method of treating cancer using amanitin derivatives | ANXA5, AADAT, ANXA3 | PTGS2 3984/4885ALDH1A1 2342/4885TSHR 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.